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Abstract 
Chronic rhinosinusitis (CRS) is a frequent chronic condition, which has origins in complex interactions between 
genetic, immunological and microbial factors. The role of auto-immunity in CRS remains unclear, although recent 
studies have started to emerge in CRS patient refractory to maximal medical management. We discuss the possible 
auto-immunity link between CRS and other skin diseases, in particular acquired bullous dermatoses, and review the 
current evidence. We raise additional considerations for auto-immunity from both research and clinical standpoints.
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Background
Chronic rhinosinusitis (CRS) is a common condition 
affecting ~13 % of the US adult population, a prevalence 
higher than that of diabetes [1]. The productivity loss 
accounting from CRS amounts to $13 billion USD [2], 
with total disease burden estimated around ~$60 billion 
USD [3]. Of particular interest are patients with refrac-
tory CRS, for whom maximal medical therapy provides 
at most marginal benefits. Refractory CRS patients are 
currently managed with multiple sinus surgeries, yet 
they still experience recurrent exacerbations requiring 
antibiotics.
The etiology of CRS is believed to be multifactorial 
(Fig. 1) [4]. Genetic predispositions most likely affect the 
role of the mucosal epithelium as a barrier, both struc-
turally and functionally [4–7]. Immunity defects have 
long been known to be implicated in CRS, in particular 
for patients resistant to treatment [8]. Evidence for this 
includes the frequent occurrence of CRS in patients 
with common variable humoral immunodeficiency [9]. 
Indirect support for implication of other immune defi-
ciency states include a disequilibrium of TH1/TH2, with 
a skewing towards stronger TH2 responses [10], aber-
rant TLR function in innate immunity [11], and chronic 
low-grade inflammation resulting from a constant feed-
forward loop of pro-inflammatory cytokines [12]. A role 
is emerging for the microbiome, particularly in a model 
governed by gene–environment interactions, which 
would have as permanent members dysbiotic bacte-
ria that colonize the chronically-inflamed mucosa to 
keep the latter dysfunctional and incorrectly repaired 
[13]. This has opened the door to novel therapeutic 
approaches, such as topical therapy with probiotics [14], 
dietary modifications [13, 15] and use of antibiotics as 
immuno-modulators and microbiome-modifiers [16] are 
all currently being investigated in the clinical setting.
Main text
Auto‑immunity in CRS
Conspicuously absent from these descriptions is the pos-
sibility of a role for auto-immunity in CRS pathogenesis. 
This is somewhat surprising as auto-immunity is a ubiq-
uitous culprit in pathologies affecting every other organ, 
thus it is likely that a similar phenomenon also occurs in 
CRS. Here we explore the auto-immune avenue, with a 
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focus on comparison with chronic auto-immune condi-
tions compromising the skin epidermal barrier.
Evidence from immune complex disorders
The deposition of auto-immune complexes in the sinus 
mucosa disrupting the sinus mucosal surface is already 
demonstrated in vasculitides [17]. Vasculitides which can 
present with sinusitis symptoms include granulomatosis 
with polyangiitis (GPA; formerly known as Wegener’s 
granulomatosis) [18] and eosinophilic granulomatosis 
with polyangiitis (EGPA; Churg-Strauss Syndrome) [19]. 
Immune complexes formed by anti-neutrophil cyto-
plasmic auto-IgG antibodies (ANCA IgG) promote 
granuloma formation in the epithelium, effectively caus-
ing a chronically-inflamed permeable barrier [20, 21]. 
Although this constitutes an interesting autoimmune 
hypothesis for CRS, the severity of disease seen in these 
patients and the low prevalence of these disorders are 
not sufficient to account for the frequency of CRS. As 
an additional consideration, these two disorders differ 
markedly in their immunologic profile: GPA predomi-
nantly displays a TH1 response while immunity in EGPA 
is shifted towards TH2 cytokines, with both disorders 
showing TH17 profiles [22].
Given the pathophysiological differences between GPA 
and CRS, we postulate that other manifestations of auto-
immunity are likely present in CRS. Since sinus mucosa 
represents an ectodermal barrier between internal 
microenvironments and external aggressors, CRS may 
share features with other barrier disorders, such as the 
skin.
Auto‑immunity and blistering skin disorders
Auto-immune sub-epidermal blistering diseases of the 
skin epithelium include various acquired bullous disor-
ders such as bullous pemphigoid, cicatricial pemphig-
oid, pemphigoid gestationis and epidermolysis bullosa 
acquisita [23]. Auto-antibodies are classically directed 
against components of the hemidesmosome-anchoring 
filament complexes or anchoring fibrils, which link the 
basement membrane to the basal keratinocyte layer via 
cytoskeletal elements [24]. These targeted proteins at the 
dermal–epidermal junction include laminins, collagens, 
integrins and other cell adhesion molecules [24].
Cicatricial, or mucous membrane, pemphigoid is a 
chronic auto-immune blistering disease that preferen-
tially affects the oral and ocular mucosae, but can also 
affect the nasal mucosa and the genitalia [23]. Cicatri-
cial pemphigoid shows the highest heterogeneity among 
auto-immune bullous conditions, with the identification 
of auto IgA and/or IgG targeting the α6 integrin subu-
nit, β4 integrin subunit, laminin 5 and/or BP180/col-
lagen XVII α1 [25]. Pemphigoid, or herpes gestationis is 
a bullous eruption of the third trimester and immediate 
post-partum that extends from the umbilicus in a cen-
trifugal direction [26]. In pemphigoid gestationis, a lin-
ear C3 deposition at the dermo-epidermal junctional 
is nearly always found, but auto IgG against BP180/col-
lagen XVII and, less commonly, BP230 can be detected 
in a third of affected pregnancies [24, 26]. Similarly to 
other dermatoses of pregnancy, pemphigoid gestationis 
displays an immune imbalance towards a stronger TH2 
response with concomitant depressed TH1 function [27]. 
Epidermolysis bullosa acquisita is characterized by recur-
ring blisters on skin and mucosae arising from IgG auto-
immunity against collagen VII [28, 29].
Insights from bullous pemphigoid
Studies from bullous pemphigoid (BP), a more common 
blistering disease of the elderly, have shed insights into 
the link between a dysbiotic flora and auto-immunity 
[30]. Auto IgG, and to a much lesser extent, auto IgA, 
against BP180/collagen XVII and BP230, a transmem-
brane protein of the hemidesmosal plaque, have been 
implicated in the pathogenesis of BP for many years [31, 
32]. Recently, auto IgE antibodies have been consistently 
isolated from a subset of patients with BP, both at their 
dermal-epidermal junction [33, 34] and in their sera 
[35, 36]. This led to the successful use of omalizumab, a 
humanized monoclonal that binds and inactivates free 
and membrane-bound IgE, to manage patients with 
standard treatment-refractory BP and elevated IgE titers 
[37, 38].
How does the presence of auto IgE in BP relate to 
CRS? First, IgE dysfunction and impairment of mast cell 
regulation and response are involved in various type I 
hypersensitivity reactions, such as asthma, allergic rhi-
nitis, atopic dermatitis, and urticaria [39, 40]. Of note, 
CRS severity is strongly associated with the presence 







Fig. 1 Chronic rhinosinusitis (CRS) as a multifactorial disease. Genetic 
factors affect the mucosal epithelium barrier, both structurally and 
functionally. Immune factors induce a strong TH2 bias, which leads 
to cytokine production and impaired innate inflammatory response. 
Microbial factors promote a dysbiotic flora and biofilm formation. 
PMNs polymorphonuclear leukocytes
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in general [41]. Serum IgE levels are elevated by 9- to 
20-fold in CRS patients (without or with nasal polyposis) 
[42]. Second, the use of omalizumab in refractory CRS 
patients with nasal polyposis has also improved symp-
tomatology, significantly [43, 44] in some studies and 
non-significantly [45] in others. In the latest randomized 
clinical trial, this significant effect was present in patients 
with both allergic and non-allergic conditions [44], sug-
gesting that the mechanisms of action is not simply lim-
ited to Type I hypersensitivity. Third, auto IgE antibodies 
can act in synergy with other auto-antibodies to mediate 
auto-immunity. In patients suffering from systemic lupus 
erythematous, auto-IgE antibodies, and the deposition of 
immune complexes containing auto-IgE, potentiate the 
effect of the more abundant auto-IgG antibodies (~20 
fold difference), leading to higher activation of innate 
inflammatory components, thus predicting a worse dis-
ease course [46]. Similarly, in CRS, auto-IgE antibod-
ies could mediate the interplay between mucosal innate 
defenses, acquired auto-immunity, and microbial agents, 
despite their relative paucity (Fig. 2).
BP180 auto‑antibodies in CRS
The discovery of autoantibodies in CRS patients is 
emerging. Anti-nuclear IgG and IgA autoantibody titers 
are elevated in CRS patients with nasal polyposis [47]. 
Recently, the discovery of elevated circulating levels of 
auto IgG against BP180/collagen XVII in CRS patients 
vs. healthy patients bring the link with bullous pemphi-
goid back into the spotlight [48]. However, deposition of 
these autoantibodies at the dermal-epidermal junction 
has been absent from the nasal mucosa of CRS patients, 
in stark contrast with BP in which it is pathogenic 
[48]. Nevertheless, auto-immunity appears to play an 
important role in CRS, and similarities to BP and other 
acquired skin bullous dermatoses are numerous.
Genetics, CRS and skin bullous conditions
Other links to epithelial blistering disorders are sug-
gested by genome-wide association studies (GWAS) of 
refractory CRS, in which several of the most common 
gene polymorphisms in CRS patients code for basement 
membrane and extra-cellular matrix proteins, including 
the laminins [6, 49]. Other polymorphisms associated 
with CRS are found in collagen- and keratin-interact-
ing genes [49]; the complete absence of these genes and 
related genes as well as aberrant gene expression can 
lead to some of the rare hereditary epidermolysis bullosa 
genodermatoses [50]. Taken together, these findings sug-
gest that interference with epithelial structure leading to 
epithelial blistering disorders in skin may mimic changes 
seen in CRS.
CRS similarities to other skin conditions
In addition to skin bullous diseases, other skin condi-
tions may yield insight into the pathophysiology of CRS. 
In chronic urticaria, dysregulated cellular function and 
autoantibodies targeting directly IgE or their recep-
tor on mast cells lead to the degranulation of mast cells 













Fig. 2 Probable interplay between auto-antibodies and known contributing factors leading to CRS. Auto-antibodies, whether IgG, IgE or IgA, influ-
ence microbial, genetic and immune factors. The latter would probably exert a feed-forward retroaction, leading to increased levels of auto-anti-
bodies. As shown in other auto-immune disorders, different classes of auto-Ig have synergistic effect on other classes. An auto-antibody targeting 
BP180 could be implicated in CRS pathogenesis. Others are likely to be discovered. Together, these factors maintain the chronic inflammatory state 
of CRS, with its altered microbial flora, dysfunctional epithelium, impaired barrier function and self-propagating inflammation
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cytokines [51]. In CRS with nasal polyposis, mast cells in 
the epithelium and glandular structures are increased in 
number and are producing abnormally-high quantities of 
proteases, thus contributing to the chronic inflammation 
and lack of complete repair [52]. Circulating auto-IgE 
antibodies have also been detected in chronic urticaria 
patients [53].
Conclusion
CRS likely arises from the interaction of genetic, immu-
nological and microbial factors. This concept may evolve 
to incorporate a contribution from auto immune disor-
ders. While experience with autoimmunity in CRS is still 
very limited, insights may be drawn from experience with 
skin epidermal disorders. Notably, in skin, auto-immu-
nity in epidermis-basement membrane unit renders the 
epidermis dysfunctional and more permeable to surface 
pathogens, which may penetrate into the dermis, ena-
bling the colonization by a dysbiotic flora that maintains 
a chronic inflammation state. This contributes to the sec-
ondary mucosal changes seen in skin disorders. These 
concepts resonate well with the disease process observed 
in CRS. The role of auto-immunity in CRS, especially in 
refractory cases, appears compelling. Given the afore-
mentioned similarities between sub-epidermal bullous 
dermatoses, focusing on the basal keratinocyte–hemides-
mosome–cytoskeleton–basal membrane interface might 
reveal additional mechanistic information. Addition-
ally, it is important to recognize that not all autoimmune 
actors are IgG auto-antibodies, and that IgA and IgE 
auto-antibodies may be more common than expected. 
Assessment for these should also be performed. As previ-
ously mentioned in the case of anti-BP180 in CRS [48], 
it is important to distinguish circulating auto-antibodies 
from those bound to the epithelium as these are probably 
significant for the maintenance of the disease. Neverthe-
less, dosing circulating auto-antibodies may serve as a 
proxy for detecting auto-immunity. As in BP and chronic 
urticaria, refractory CRS might also feature auto-IgE 
antibodies.
Suggestions for further studies include (1) verifying the 
presence of other circulating auto-antibodies targeting 
the dermal–epidermal junction and the hemidesmosome 
plaque in CRS patients, and (2) determining the presence 
of auto-antibodies on sinus biopsies/tissues and nasal 
polyps from CRS patients using dermato-histopatholog-
ical techniques.
On the clinical side, implications of these findings are 
twofold. First, investigation of CRS should include the 
possibility of auto-immunity. Second, clinicians may 
have to consider biological and targeted therapies aimed 
at decreasing auto-immunity in refractory CRS patients. 
Experience with those treatment regimens from diseases 
involving other body systems should come in handy for 
CRS. However, therapeutic agents used in other disor-
ders will require prospective assessment prior to clinical 
deployment.
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